KR20140117433A - 재조합 독소를 포함하는, 클로스트리디움 디피실레에 대한 백신 - Google Patents

재조합 독소를 포함하는, 클로스트리디움 디피실레에 대한 백신 Download PDF

Info

Publication number
KR20140117433A
KR20140117433A KR1020147020672A KR20147020672A KR20140117433A KR 20140117433 A KR20140117433 A KR 20140117433A KR 1020147020672 A KR1020147020672 A KR 1020147020672A KR 20147020672 A KR20147020672 A KR 20147020672A KR 20140117433 A KR20140117433 A KR 20140117433A
Authority
KR
South Korea
Prior art keywords
asn
ile
leu
lys
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020147020672A
Other languages
English (en)
Korean (ko)
Inventor
존 헨리 하인리히스
장-뤽 보드머
수잔 린 세코어
아론 루디 괴르케
이베트 카로-아귈라
마리-피에르 젠틸레
멜라니 에스. 호르톤
매튜 라이언 미자이에브스키
줄리 엠. 스키너
파울루스 야코부스 안토니우스 손더마이예르
샤이암순다르 수브라마니안
카린 후버디나 안토니아 판 데르 하예덴-리에프켄스
수 왕
진푸 셰
레이첼 플로라 소코노스틀레
줄리 케이. 조르만
Original Assignee
머크 샤프 앤드 돔 코포레이션
인터벳 인터내셔널 비.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 머크 샤프 앤드 돔 코포레이션, 인터벳 인터내셔널 비.브이. filed Critical 머크 샤프 앤드 돔 코포레이션
Publication of KR20140117433A publication Critical patent/KR20140117433A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1051Hexosyltransferases (2.4.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1077Pentosyltransferases (2.4.2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020147020672A 2012-01-27 2013-01-25 재조합 독소를 포함하는, 클로스트리디움 디피실레에 대한 백신 Withdrawn KR20140117433A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261591631P 2012-01-27 2012-01-27
US61/591,631 2012-01-27
US201261596419P 2012-02-08 2012-02-08
US61/596,419 2012-02-08
US201261703754P 2012-09-20 2012-09-20
US61/703,754 2012-09-20
PCT/US2013/023189 WO2013112867A1 (en) 2012-01-27 2013-01-25 Vaccines against clostridium difficile comprising recombinant toxins

Publications (1)

Publication Number Publication Date
KR20140117433A true KR20140117433A (ko) 2014-10-07

Family

ID=48873956

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147020672A Withdrawn KR20140117433A (ko) 2012-01-27 2013-01-25 재조합 독소를 포함하는, 클로스트리디움 디피실레에 대한 백신

Country Status (14)

Country Link
US (1) US9388394B2 (cg-RX-API-DMAC7.html)
EP (1) EP2807186A4 (cg-RX-API-DMAC7.html)
JP (2) JP2015506948A (cg-RX-API-DMAC7.html)
KR (1) KR20140117433A (cg-RX-API-DMAC7.html)
CN (1) CN104039816B (cg-RX-API-DMAC7.html)
AR (1) AR089797A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013211973B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014018432A8 (cg-RX-API-DMAC7.html)
CA (1) CA2856443A1 (cg-RX-API-DMAC7.html)
IN (1) IN2014CN04187A (cg-RX-API-DMAC7.html)
MX (1) MX351074B (cg-RX-API-DMAC7.html)
RU (1) RU2014134365A (cg-RX-API-DMAC7.html)
TW (1) TW201335178A (cg-RX-API-DMAC7.html)
WO (1) WO2013112867A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2968629T3 (es) 2011-04-22 2024-05-13 Wyeth Llc Composiciones relacionadas con una toxina mutante de Clostridium difficile y sus procedimientos
JP6084631B2 (ja) * 2011-12-08 2017-02-22 ノバルティス アーゲー Clostridiumdifficile毒素ベースのワクチン
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
JP2016518374A (ja) * 2013-04-22 2016-06-23 ボード オブ リージェンツ オブ ザ ユニバーシテイ オブ オクラホマ クロストリジウム・ディフィシルワクチン及び使用方法
WO2014197651A1 (en) * 2013-06-05 2014-12-11 Tufts University Atoxic recombinant holotoxins of clostridium difficile as immunogens
EP3007724B1 (en) 2013-06-14 2023-07-05 Sanofi Pasteur Inc. Compositions and methods of immunizing against c. difficile
LT3160500T (lt) * 2014-06-25 2019-10-25 Glaxosmithkline Biologicals Sa Clostridium difficile imunogeninė kompozicija
JP2017212882A (ja) * 2014-10-10 2017-12-07 学校法人 名城大学 アセチルエステラーゼ及びその利用
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US20180110849A1 (en) 2015-05-15 2018-04-26 Sanofi Pasteur, Inc. Methods for immunizing against clostridium difficile
TW201718627A (zh) 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
US11969461B2 (en) 2016-03-02 2024-04-30 Merz Pharma Gmbh & Co. Kgaa Composition comprising botulinum toxin
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US12071666B2 (en) * 2016-12-14 2024-08-27 Merck Sharp & Dohme Llc Human genetic markers associated with response to treatments that target clostridium difficile toxin B
US10668140B2 (en) 2017-02-24 2020-06-02 University Of South Floirida Non-toxigenic Clostridium difficile spores for use in oral vaccination
US11123419B2 (en) * 2017-03-15 2021-09-21 Novavax, Inc. Methods and compositions for inducing immune responses against Clostridium difficile
US10555992B2 (en) 2017-05-31 2020-02-11 University Of South Florida Immunogenic proteins against clostridium difficile
MX388528B (es) * 2017-06-09 2025-03-20 Hipra Scient S L U Vacuna que comprende toxoides de clostridium.
EP3642222A1 (en) 2017-06-20 2020-04-29 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with increased duration of effect
EP3649143B1 (en) 2017-07-06 2022-08-31 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with increased duration of effect
US10933126B2 (en) 2018-05-03 2021-03-02 The Board Of Regents Of The University Of Oklahoma Clostridium difficile immunogenic compositions and methods of use
WO2020078420A1 (en) * 2018-10-17 2020-04-23 Eternity Biomedical Laboratories, Inc. Immunogenic preparations and methods against clostridium difficile infection
CN110041437B (zh) * 2019-04-29 2020-12-25 中国兽医药品监察所 一种无毒性破伤风毒素和诺维梭菌α毒素重组融合蛋白
CN110607314B (zh) * 2019-10-31 2022-09-23 四川农业大学 一种TcdB RBD基因、重组RBD蛋白和应用
CN112442472B (zh) * 2020-11-30 2023-05-26 四川大学华西医院 抗艰难梭菌的重组乳酸乳球菌、活载体疫苗及其制备方法
CN118613492A (zh) * 2022-01-30 2024-09-06 西湖大学 Tfpi结合多肽及其用途
JP2023134918A (ja) * 2022-03-15 2023-09-28 株式会社荏原製作所 研磨方法および研磨装置
WO2025029561A2 (en) * 2023-07-28 2025-02-06 University Of South Florida Vaccine containing rbd2 of cdtb component from binary toxin cdt of clostridioides difficile

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919665A (en) 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
AU746859B2 (en) 1997-06-20 2002-05-02 Imperial College Of Science, Technology And Medicine Immonogenic fragments of toxin a of clostridium difficile
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
DE69829400T2 (de) 1997-10-20 2006-04-13 Acambis, Inc., Cambridge Passive immunisierung gegen durch clostridium difficile verursachte krankheit
AU781027B2 (en) 1999-04-09 2005-04-28 Department Of Health & Human Services Recombinant toxin a protein carrier for polysaccharide conjugate vaccines
US7226597B2 (en) 2002-06-17 2007-06-05 The Board Of Regents Of The University Of Oklahoma Mutants of Clostridium difficile toxin B and methods of use
EP1699814A4 (en) 2003-12-08 2009-01-14 Hybridon Inc MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF COMPOUNDS FORMED FROM SMALL OLIGONUCLEOTIDES
PT1766093E (pt) 2004-02-06 2011-08-24 Univ Massachusetts Anticorpos contra toxinas de clostridium difficile e utilizações dos mesmos
US7470674B2 (en) 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
EP2004220B1 (en) * 2006-03-30 2015-07-01 Embrex Inc. Methods and compositions for vaccination of poultry
DK2396652T3 (da) * 2009-02-11 2018-01-29 Cedars Sinai Medical Center Diagnose af inflammatorisk tarmsyndrom baseret på cytoletalt udspilende toksin
CA2752815A1 (en) * 2009-02-20 2010-08-26 Health Protection Agency Antibodies to clostridium difficile toxins
EP2470664A4 (en) * 2009-08-27 2013-01-16 Synaptic Res Llc NEW PROTEIN RELEASE SYSTEM FOR GENERATING INDUCED PLURIPOTENTAL STEM CELLS OR TISSUE-SPECIFIC CELLS
US10046040B2 (en) 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
EP2519257A4 (en) 2009-12-02 2014-10-15 Univ Tufts ATOXIC RECOMBINANT HOLOTOXINS FROM CLOSTRIDIUM DIFFICILE AS IMMUNOGENESIS
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
DK2753352T4 (da) 2010-09-03 2022-09-12 Valneva Austria Gmbh Isoleret polypeptid af toxin a og toxin b proteinerne fra c. difficile og anvendelser deraf
US8431361B2 (en) * 2010-09-17 2013-04-30 Board Of Regents Of The University Of Oklahoma Bacterial cells, optimized nucleotide sequences and methods for improved expression of recombinant Clostridium difficile toxin B
ES2968629T3 (es) 2011-04-22 2024-05-13 Wyeth Llc Composiciones relacionadas con una toxina mutante de Clostridium difficile y sus procedimientos

Also Published As

Publication number Publication date
CA2856443A1 (en) 2013-08-01
JP2015506948A (ja) 2015-03-05
CN104039816A (zh) 2014-09-10
AR089797A1 (es) 2014-09-17
MX2014009106A (es) 2014-11-10
JP2017141226A (ja) 2017-08-17
MX351074B (es) 2017-09-28
BR112014018432A8 (pt) 2017-07-11
AU2013211973A1 (en) 2014-06-12
CN104039816B (zh) 2018-02-09
AU2013211973B2 (en) 2017-10-12
US20150044250A1 (en) 2015-02-12
US9388394B2 (en) 2016-07-12
EP2807186A4 (en) 2016-01-27
BR112014018432A2 (cg-RX-API-DMAC7.html) 2017-06-20
EP2807186A1 (en) 2014-12-03
IN2014CN04187A (cg-RX-API-DMAC7.html) 2015-07-17
TW201335178A (zh) 2013-09-01
WO2013112867A1 (en) 2013-08-01
RU2014134365A (ru) 2016-03-20

Similar Documents

Publication Publication Date Title
KR20140117433A (ko) 재조합 독소를 포함하는, 클로스트리디움 디피실레에 대한 백신
AU2020230248B2 (en) Compositions relating to a mutant Clostridium difficile toxin and methods thereof
AU2019203159B2 (en) Compositions and methods relating to a mutant clostridium difficile toxin
AU2017371484B2 (en) Bacteriophage compositions comprising respiratory antibacterial phages and methods of use thereof
RU2725726C2 (ru) Бактериофаги, фаговые пептиды и способы их применения
KR101907434B1 (ko) C. 디피실의 a 독소 및 b 독소 단백질의 분리된 폴리펩타이드 및 이의 용도
KR20140101835A (ko) 클로스트리듐 디피실레 톡신-기반 백신
AU2018343217B2 (en) Compositions and methods for eliciting an immune response against Clostridium difficile
KR20150056540A (ko) 백신으로서의 클로스트리듐 디피실 폴리펩티드
KR102224897B1 (ko) 신규한 폴리펩타이드 및 이를 포함하는 그람음성균에 대한 항생제
DK2576604T3 (en) DIFFOCINES AND METHODS OF USING THEREOF
AU2021240230B2 (en) Vaccines and vaccine components for inhibition of microbial cells
RU2773880C1 (ru) Композиции, относящиеся к мутантному токсину CLOSTRIDIUM DIFFICILE, и способы их применения
KR20160146217A (ko) 비브리오 패혈증균의 시스테인 단백질 분해효소 도메인 유래 재조합 단백질 및 이의 용도

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140723

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid